CytomX is unlocking the potential of antibody therapeutics in oncology with highly targeted Probody™ therapeutics.

from http://cytomx.com/about/

Research Grants 2 show all


$208K
2008

$260.9K
2009

Patents 282show all

  • 76
    C07K - Peptides
  • 60
    A61K - Preparations for medical, dental, or toilet purposes
  • 13
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 12
    C12N - Microorganisms or enzymes
  • 7
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 2
    B01L - Chemical or physical laboratory apparatus for general use
  • 2
    B03C - Magnetic or electrostatic separation of solid materials from solid materials or fluids
  • 1
    A61F - Filters implantable into blood vessels

Clinical Trials 13show all

11Phase 1/Phase 21Phase 11Phase 2

SEC Filings show all


58
8-K

13
10-Q

8
D

4
10-K

1
S-1

Contact Information

South San Francisco, CA
United States

SEC Form D Funding Events

DateOfferedSoldType
2015-01-06$29,999,999$16,499,999Equity
2012-08-10$25,999,999$12,599,999Equity
2010-09-28$524,994$524,994Other
2010-09-28$652,903$652,903Other
2010-09-28$30,000,000$10,000,000Other
2010-09-28$2,660,000$2,660,000Other
2010-09-28$102,097$102,097Other

Key Executives

  • Nancy Stagliano
    Executive Officer, Director
  • Frederick W. Gluck
    Executive Officer, Director
  • Alan Heeger
    Director
  • Gary Wilcox
    Director
  • Michael E. Pfau
    Executive Officer
  • Frederick Gluck
    Executive Officer, Director
  • Sean McCarthy
    Executive Officer, Director
  • Fletcher Payne
    Executive Officer
  • Hoyoung Huh
    Director
  • Neil Exter
    Director
  • Charles Homcy
    Director
  • Tim Shannon
    Director
  • Elaine V. Jones
    Director